Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;7(5):9267.
doi: 10.1007/s12410-014-9267-z.

Cardiovascular Magnetic Resonance Imaging of Myocardial Interstitial Expansion in Hypertrophic Cardiomyopathy

Affiliations
Review

Cardiovascular Magnetic Resonance Imaging of Myocardial Interstitial Expansion in Hypertrophic Cardiomyopathy

Timothy C Wong. Curr Cardiovasc Imaging Rep. 2014.

Abstract

Hypertrophic cardiomyopathy (HCM) is a cardiovascular genetic disease with a varied clinical presentation and phenotype. Although mutations are typically found in genes coding for sarcomeric proteins, phenotypic derangements extend beyond the myocyte to include the extracellular compartment. Myocardial fibrosis is commonly detected by histology, and is associated with clinical vulnerability to adverse outcomes. Over the past decade, the noninvasive visualization of myocardial fibrosis by cardiovascular magnetic resonance (CMR) techniques has garnered much interest given the potential applications toward improving our understanding of pathophysiologic mechanisms of disease, as well as diagnosis and prognosis. Late gadolinium enhancement (LGE) imaging techniques are able to detect focal (typically replacement) fibrosis. Newer CMR techniques that measure absolute T1 relaxation time allow the quantification of the entire range of focal to diffuse (interstitial) fibrosis and may overcome potential limitations of LGE. This review will discuss the methodology and current status of these novel techniques, with a focus on extracellular volume fraction (ECV). Recent findings describing ECV measurement in HCM will be summarized.

Keywords: Cardiovascular magnetic resonance; Extracellular volume fraction; Gadolinium contrast; Hypertrophic cardiomyopathy; Myocardial fibrosis; T1 mapping.

PubMed Disclaimer

Conflict of interest statement

Timothy C. Wong declares that he has no conflict of interest.

Figures

Fig. 1
Fig. 1
(Adapted from Wong et al [32], with permission from Lippincott Williams & Wilkins - Wolters Kluwer Health). Measurement of pre and postcontrast T1 in an individual with normal ECV. Short axis imaging at varying time points (precontrast images top row, postcontrast images bottom row) along with the corresponding fitting curves used to derive absolute T1 measurement. Calculations are performed at the pixel level to generate pre and postcontrast T1 maps
Fig. 2
Fig. 2
CMR images of a patient with hypertrophic cardiomyopathy. a Four-chamber steady state free precession (SSFP) image demonstrating asymmetric septal hypertrophy. b Three-chamber SSFP image. c Midventricular short axis LGE image ~15 minutes postgadolinium contrast showing focal LGE in the vicinity of the right ventricular insertion point. d Precontrast T1 map. e postcontrast T1map ~ 20 minutes postgadolinium contrast. f ECV map calculated using the T1 data and hematocrit. The horizontal dashed white line notes the color range of the upper limit of normal of ECV (~29.5 % at our center). The black arrows point to the anterior septal region where more diffuse fibrosis is identified, which was not as readily apparent on the LGE image (panel (c). Note: panels c, d, e, f are the same short axis slice

References

    1. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e783–831. doi: 10.1161/CIR.0b013e318223e2bd. - DOI - PubMed
    1. Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 2004;116:14–8. doi: 10.1016/j.amjmed.2003.05.009. - DOI - PubMed
    1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785–9. doi: 10.1161/01.CIR.92.4.785. - DOI - PubMed
    1. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60:705–15. doi: 10.1016/j.jacc.2012.02.068. - DOI - PubMed
    1. Sherrid MV. Implantable cardioverter-defibrillators for children and adolescents at high risk for sudden death from hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61:1536–8. doi: 10.1016/j.jacc.2013.01.038. - DOI - PubMed

LinkOut - more resources